cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

2018/03/01 by David N. Louis, Caterina Giannini, David Capper +11 · 28 citations
Medicine · #Glioma Diagnosis and Treatment #Meningioma and schwannoma management #Neuroblastoma Research and Treatments

paper · doi:10.1007/s00401-018-1826-y

Citations

• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

Cited by

• Recurrent oligodendroglioma with changed 1p/19q status
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know
• Reconstructing the molecular life history of gliomas. [europepmc]
• Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. [europepmc]
• Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. [europepmc]
• High frequency of H3 K27M mutations in adult midline gliomas. [europepmc]
• The Misclassification of Diffuse Gliomas: Rates and Outcomes. [europepmc]
• Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. [europepmc]
• cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. [europepmc]
• Molecular pathology of tumors of the central nervous system. [europepmc]
• Genetic and molecular epidemiology of adult diffuse glioma. [europepmc]
• The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. [europepmc]
• BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. [europepmc]
• Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain. [europepmc]
• The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. [europepmc]
• Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. [europepmc]
• A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. [europepmc]
• Clinical Management of Diffuse Low-Grade Gliomas. [europepmc]
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. [europepmc]
• Major Features of the 2021 WHO Classification of CNS Tumors. [europepmc]
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know. [europepmc]
• The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview. [europepmc]
• The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics. [europepmc]
• Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification. [europepmc]
• Signaling pathways in brain tumors and therapeutic interventions. [europepmc]
• Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. [europepmc]
• Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. [europepmc]